PreludeDx™ Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio
/PRNewswire/-- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that...